Cyclin-dependent kinase 7

Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

Retrieved on: 
Wednesday, July 19, 2023
Oncology, Professional Services, Health, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Pharma, AACR, Cancer, Hope, Lung cancer, PDX, SCLC, Cyclin, American Association for Cancer Research, Patient, Cell cycle, Annual general meeting, Ovarian cancer, Carcinoma, Stomach, Cyclin-dependent kinase 7, Breast cancer, Pharmaceutical industry

Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the selection of CID-078 for its first clinical development program.

Key Points: 
  • Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the selection of CID-078 for its first clinical development program.
  • CID-078 is the first-and-only-in-class dual inhibitor of Cyclins A and B, which play essential roles in regulating cell cycle progression.
  • Inhibiting Cyclins A and B selectively induces synthetic lethality in certain cancers exhibiting cell cycle dysregulation while sparing healthy cells.
  • Circle Pharma recently presented pre-clinical data for its dual Cyclin A/B inhibitors at this year’s American Association for Cancer Research (AACR) Annual Meeting.

Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
NRAS, AACR, Cyclin-dependent kinase 7, American Association for Cancer Research, BRAF, Research, MEK, Binimetinib, CDK12, Investment, Patient, SAN, Annual general meeting, Growth, Neoplasm, Society, KNTE, RAF, Pharmaceutical industry, Cryptocurrency

(Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the first quarter of 2023 and recent corporate updates.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the first quarter of 2023 and recent corporate updates.
  • First quarter research and development expenses for 2023 were $26.5 million, compared to $19.6 million for the same period in 2022.
  • First quarter general and administrative expenses for 2023 were $8.1 million, compared to $7.4 million for the same period in 2022.
  • First quarter net loss for 2023 was $32.9 million, compared to $26.9 million for the same period in 2022.

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Retrieved on: 
Thursday, August 5, 2021
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, KRAS, Roche, APL, Venetoclax, Gene, Safety, LinkedIn, Clinical trial, MDS, Compte rendu, Acute myeloid leukemia, Annual report, Acute promyelocytic leukemia, Twitter, CDK, ESMO, ID, Immunotherapy, Research, Genome, G&A, Lists of people executed in the United States, Security (finance), Lung, Investor, BRAF, Azacitidine, Congress, Fulvestrant, Workforce, Cyclin-dependent kinase 7, Rara, Breast, Arsenic trioxide, Initiate, Nasdaq, U.S. Securities and Exchange Commission, Webcast, Freedom, GBT, Private Securities Litigation Reform Act, Kol, Hematology, Government, AML, Selective estrogen receptor degrader, Patient, COVID-19, Ovarian cancer, Colorectal cancer, Phase 1, Histology, Pharmaceutical industry, Medical device

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.
  • Research and development expenses were $25.8 million for the first quarter of 2021, as compared to $14.8 million for the second quarter of 2020.
  • General and administrative (G&A) expenses were $5.5 million for the second quarter of 2021, as compared to $5.1 million for the second quarter of 2020.
  • ET to discuss these second quarter 2021 financial results and provide a corporate update.

Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer

Retrieved on: 
Thursday, August 5, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Lung, Cancer, BRAF, Clinical trial, U.S. Securities and Exchange Commission, Freedom, Compte rendu, Private Securities Litigation Reform Act, Acute myeloid leukemia, Annual report, Government, Roche, Acute promyelocytic leukemia, Congress, Patient, COVID-19, Twitter, Workforce, Society, Cyclin-dependent kinase 7, Rara, Gene, Colorectal cancer, Rb, Immunotherapy, Histology, CRC, DNA, Arsenic trioxide, Safety, Genome, LinkedIn, Nasdaq, Security (finance), Pharmaceutical industry, Vaccine

Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.

Key Points: 
  • Preclinical data has shown that CDK7 inhibition enhances the anti-tumor activity of PD-L1 inhibition, providing a strong rationale for combining SY-5609 and atezolizumab.
  • Notably, this trial marks the first clinical investigation of a CDK7 inhibitor with an immunotherapy, and we look forward to working with Roche to evaluate the potential of this novel combination in patients with BRAF-mutant colorectal cancer.
  • Under the terms of the agreement, Roche will sponsor and conduct the Phase 1/1b study to evaluate the safety, tolerability and preliminary efficacy of the combination and will assume all costs associated with the study.
  • In exchange for providing SY-5609, Syros will receive access to the data on SY-5609 in combination with atezolizumab.

Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors

Retrieved on: 
Monday, December 7, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Branches of biology, Exelixis, Biology, Cyclin-dependent kinase 7, C-Met, Investigational New Drug, Aurigene, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigenes novel CDK7 inhibitor under the companies July 2019 agreement .

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigenes novel CDK7 inhibitor under the companies July 2019 agreement .
  • Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102 (formerly AUR102).
  • Exelixis also announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate XL102 alone or in combination therapy for the treatment of inoperable locally advanced or metastatic solid tumors.
  • We are excited to begin clinical development for XL102 following the FDAs recent acceptance of our IND.

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Retrieved on: 
Saturday, October 24, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Cell Cycle, Proteins, Cyclin-dependent kinase 7

SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor.

Key Points: 
  • SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor.
  • As we move forward in this trial, we are committed to fully exploring the potential of SY-5609.
  • The data showed that:
    SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity.
  • Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021.

Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

Retrieved on: 
Friday, October 9, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, European Organisation for Research and Treatment of Cancer, Branches of biology, Cyclin-dependent kinase 7, Ena, Exelixis, Abstract, Biology, Articles, Aurigene, Exelixis

Exelixis has an exclusive option for AUR102 under its July 2019 exclusive collaboration, option and license agreement with Aurigene .

Key Points: 
  • Exelixis has an exclusive option for AUR102 under its July 2019 exclusive collaboration, option and license agreement with Aurigene .
  • The new data will be presented in a poster (Abstract 170) at the 32nd EORTC-NCI-AACR (ENA) Symposium, which is being held virtually on October 24-25, 2020.
  • The data to be presented at ENA 2020 demonstrate that AUR102 effectively engages CDK7 and inhibits a key mediator of the cell cycle and transcription.
  • Exelixis is also contributing research funding to Aurigene to facilitate discovery and preclinical development work on all six programs.

Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers

Retrieved on: 
Wednesday, January 29, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Cell Cycle, Gene expression, Proteins, RNA, Cyclin-dependent kinase 7, Regulation of gene expression, CDK12

Together, these presentations underscore our leadership in CDK inhibition and, more broadly, in the field of gene control, said Eric R. Olson, Ph.D., Syros Chief Scientific Officer.

Key Points: 
  • Together, these presentations underscore our leadership in CDK inhibition and, more broadly, in the field of gene control, said Eric R. Olson, Ph.D., Syros Chief Scientific Officer.
  • Syros scientists studied the transcriptional effects of selective CDK7 and CDK12 inhibition in an ovarian cancer cell line, marking the first reported direct comparison of these two approaches.
  • CDK12 inhibition preferentially decreased expression of genes with longer transcripts, a phenomenon that was not observed with CDK7 inhibition.
  • The DNA double-stranded break repair pathway is enriched for genes with longer transcripts that are preferentially downregulated by CDK12 inhibition.

Syros Announces Update on Selective CDK7 Inhibitor Portfolio

Retrieved on: 
Thursday, October 17, 2019
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Cell Cycle, Cyclin-dependent kinase 7, Proteins

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its portfolio of selective cyclin-dependent kinase 7 (CDK7) inhibitors.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its portfolio of selective cyclin-dependent kinase 7 (CDK7) inhibitors.
  • The Company has decided to prioritize the development of its highly selective and potent oral CDK7 inhibitor, SY-5609, and to discontinue further development of SY-1365, its intravenous (IV) CDK7 inhibitor.
  • Based on these factors, Syros has made a CDK7 portfolio decision to focus on SY-5609.
  • We believe in selective CDK7 inhibition as a potentially transformative targeted approach for difficult-to-treat cancers, said Nancy Simonian, M.D., Chief Executive Officer of Syros.